The U.S. Food and Drug Administration (FDA) has granted fast track designation to Alessa Therapeutics for its lead product ...

Alessa Therapeutics ("Alessa"), a clinical-stage biopharmaceutical company advancing novel localized drug delivery technology for the treatment of early-stage prostate cancers, today announced that ...

Decades ago, doctors created a test to determine which breast cancer patients should receive hormone therapy. Now, researchers are using the same tactics to advance prostate cancer treatment.

The UCLA trial is currently enrolling patients.

Survivorship in metastatic prostate cancer is seen as chronic management, focusing on quality of life through physical and emotional management. Carotuximab combined with Erleada shows a favorable ...

Every prostate cancer journey begins with a clear understanding of the diagnosis. This isn’t a “one-size-fits-all” disease, and treatment plans are highly personalized. “When we’re evaluating a case ...

In preclinical prostate cancer models, HLD-0915 treatment resulted in tumor shrinkage and declines in prostate-specific antigen. The Food and Drug Administration (FDA) has granted Fast Track ...

Fast Track Designation Highlights Potential of Enolen to Address Unmet Medical Need for Patients with Low to Intermediate Risk, Localized Prostate Cancer Company Expects to Provide Initial Findings ...